LifeStance Health Group, Inc. Form 8-K Summary
Reporting date: May 20, 2022; the report was signed and includes a press release dated May 23, 2022. The filing concerns executive leadership changes and related compensation arrangements, not financial results.
Business Context and Reporting Period
- LifeStance Health Group, Inc. is a Delaware corporation whose common stock trades on Nasdaq under the symbol LFST.
- The company reported under Item 5.02, relating to the departure and appointment of certain officers, and Item 7.01, relating to Regulation FD disclosure.
- LifeStance is identified as an emerging growth company.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial statement metrics.
Material Changes
- Gwendolyn Booth, Chief Operating Officer, notified the company of her decision to retire, effective July 1, 2022.
- Following retirement, Ms. Booth will serve as a company consultant and executive director of the LifeStance Health Foundation.
- Danish Qureshi, previously Chief Growth Officer, was appointed Chief Operating Officer effective July 1, 2022.
Compensation, Agreements, and Other Unusual Items
- Under the separation and consulting arrangements, Ms. Booth will receive $13,750 per month for consulting services, including her Foundation role.
- Previously granted restricted stock units will remain eligible to vest based on continued service, with the schedule modified so that one-third may vest on the first anniversary of the grant date and the remaining two-thirds on the second anniversary.
- Company equity owned by Ms. Booth will remain subject to specified transfer restrictions until the two-year anniversary of the company’s initial public offering.
- Ms. Booth agreed to release claims in favor of the company and its affiliates.
- The filing states that the separation documents will be filed as exhibits to the company’s Form 10-Q for the quarter ending June 30, 2022.
Guidance, Outlook, and Risks
The filing provides no financial guidance or operating outlook. The principal disclosed risk or uncertainty is the potential impact of the COO transition and the terms of the consulting, equity vesting, and transfer-restriction arrangements. The filing text refers to May 20, 2021 in describing Ms. Booth’s notice, which appears inconsistent with the May 20, 2022 report date and should be verified against the filed document.
Investor Verification Items
- Verify the effective retirement and appointment date of July 1, 2022.
- Review the complete separation, consulting, RSU amendment, and stock transfer amendment agreements when filed with the Form 10-Q.
- Confirm the aggregate number and accounting treatment of Ms. Booth’s continuing RSUs and any resulting compensation expense.
- Confirm the duration and scope of the equity transfer restrictions.
- Verify the apparent year discrepancy regarding the date Ms. Booth notified the company of her retirement.